Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Evaluation of Safety and Immune Response of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: Results from a Randomized Placebo-Controlled Phase 1 Trial
To investigate the safety, reactogenicity, and immunogenicity of a Clostridioides difficile vaccine candidate targeting the F2 antigen with and without the AS01 adjuvant in healthy adults.
Key Findings:
Solicited adverse events were transient and most frequent in the adjuvanted group.
No serious adverse events were related to the vaccine.
Immunogenicity was significantly higher in the adjuvanted group compared to the non-adjuvanted group.
A third dose enhanced immune response in subjects with low baseline neutralization titers.
Interpretation:
The GSK C. difficile vaccine candidate is immunogenic and well-tolerated, particularly when combined with the AS01 adjuvant, suggesting significant potential for effective prevention of C. difficile infections and implications for public health.
Limitations:
Study conducted at a single center, limiting generalizability.
Small sample sizes in some groups may affect the robustness of the findings.
Conclusion:
The findings support further development of the GSK C. difficile vaccine candidate, particularly with the AS01 adjuvant, for preventing C. difficile infections.
by Isabel Leroux-Roels, Azhar Alhatemi, Magalie Caubet, Fien De Boever, Bertrand de Wergifosse, Mohamed El Idrissi, Guilherme S Ferreira, Bart Jacobs, Axel Lambert, Sandra Morel, Charlotte Servais, Juan Pablo Yarzabal
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
